To include your compound in the COVID-19 Resource Center, submit it here.

Semprana dihydroergotamine regulatory update

Allergan said FDA issued the third complete response letter for a resubmitted NDA for Semprana dihydroergotamine for the acute treatment of migraines in adults. The company said

Read the full 272 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE